Status:
COMPLETED
Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults
Lead Sponsor:
Mayo Clinic
Conditions:
Immune Response
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
Our group has shown that HAART increases the thymic production of naïve T cells in the healthy adult, thereby boosting the immune system. We propose to investigate the amount of and length of Nelfinav...
Detailed Description
Blood will be collected at several time points during the study. DNA will be isolated from peripheral blood lymphocytes (PBL) and assessed for signal point (sj) TREC content relative to genomic CCR5 c...
Eligibility Criteria
Inclusion
- Healthy individuals between the ages of 20 and 100. Exclusion criteria include the following: HIV, HBV/HCV positive, known sensitivity to protease inhibitors, oral intake contraindicated, diabetes mellitus diagnosed within the last six months, and any of the following medications: cisapride, amiodarone, terfenadine, rifampin/rifabutin, phenobarbital, pinozide, St. John's wort, ergot derivatives, quinidine, astemazole, carbemazapine, phenytoin, midazolam, triazolam, and simvastatin.
Exclusion
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00346619
Start Date
October 1 2005
End Date
October 1 2007
Last Update
January 20 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905